Efficacy and Safety of Qili Qiangxin Capsules for Chronic Heart Failure: a Multicenter, Randomized, Double Blinding, Parallel Placebo-Controlled Trial

INTERVENTION: B:Standard treatment of CHF + placebo Capsule 4 granules t.i.d., po for 12 wks. ;A:Standard treatment of CHF + Qili Qiangxin Capsule 4 granules t.i.d., po for 12 wks.; CONDITION: chronic heart failure ICD‐10 150 PRIMARY OUTCOME: NT‐proBNP;composite event; SECONDARY OUTCOME: 6 minute walking test;NYHA classification;LVEF and LVED;Minnesota living with heart failure questionnaire;Change of NT‐proBN; INCLUSION CRITERIA: 1. Male or female subjects aged 18‐75; 2. Voluntarily signed the informed consent and having good adherence; 3. Patients with history or clinical symptoms of chronic heart failure (CHF) more than 3 months; 4. Left ventricle eject fraction <=40% (by modified Simpson method); 5. NYHA classification stage II‐III, or IV with stable hemodynamics and needing no intravenous medicine; 6. Serum NT‐proBNP>=450pg/ml; 7. Patients have received standard medical treatment for more than 2 wks and no modification of dosage or intravenous administration has been given.